Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANAVEX2-73 in Rett Syndrome
NCT03941444Phase 3Completed
- Sponsor
- Anavex Life Sciences Corp.
- Start
- May 2019
- Primary completion
- Sep 2021
- Modality
- Classical Binding Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of blarcamesine in Rett syndrome (RTT), sponsored by Anavex Life Sciences Corp.. Started May 2019; status: completed.
02
Drugs
blarcamesine
03
Conditions
Rett syndrome (RTT)
Beyond the preview
Go deeper on NCT03941444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03941444.